• Company
• DHP Korea faces reimb. reevaluations for its HA eye drops
• by Nho, Byung Chul Apr 18, 2022 05:58am

• Policy
• Reimb. suspension on rebate drugs unconstitutional
• by Lee, Tak-Sun Apr 18, 2022 05:58am

• Policy
• Utilizing RWD for Re-evaluation of Old Drugs
• by Lee, Hye-Kyung Apr 18, 2022 05:58am

• Product
• Gov discusses presenting regulatory sandboxes for ER OTC
• by Jung, Heung-Jun Apr 18, 2022 05:57am

• Policy
• Will losses from drug price cut dispositions be recovered?
• by Lee, Jeong-Hwan Apr 15, 2022 06:03am

• Company
• Dividend payout for Pfizer is 12.48 million won
• by Chon, Seung-Hyun Apr 15, 2022 06:03am

• Company
• Acromegaly drug ‘Somavert’ lands in ‘Big 5’ hospitals
• by Eo, Yun-Ho Apr 15, 2022 06:03am

• Opinion
• [Reporter's eyes] Despite Tessentrick's high sales
• by Apr 15, 2022 06:03am

• Company
• Artiva expands contract to develop dell therapy with MSD
• by Eo, Yun-Ho Apr 15, 2022 06:03am

• InterView
• "Will make R&D partnerships, introduce new drugs in Korea"
• by Apr 14, 2022 05:56am